CAS 1029712-80-8: Capmatinib

Description: Capmatinib is a targeted therapy classified as a small molecule inhibitor, primarily used in the treatment of certain types of non-small cell lung cancer (NSCLC) that harbor mutations in the MET gene. Its mechanism of action involves selective inhibition of the MET receptor tyrosine kinase, which plays a crucial role in tumor growth and metastasis. Capmatinib is known for its oral bioavailability and is typically administered in tablet form. The substance exhibits a favorable pharmacokinetic profile, with a relatively short half-life, necessitating multiple daily doses to maintain therapeutic levels. It is metabolized primarily by the liver, and its elimination is influenced by various cytochrome P450 enzymes. Capmatinib has been associated with specific side effects, including gastrointestinal disturbances and potential liver function alterations, which require monitoring during treatment. As a targeted therapy, it represents a significant advancement in personalized medicine, offering a treatment option for patients with MET-driven malignancies.

Formula: C₂₃H₁₇FN₆O

InChI: InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)

InChI key: InChIKey=LIOLIMKSCNQPLV-UHFFFAOYSA-N

SMILES: O=C(NC)C=1C=CC(=CC1F)C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4

Synonyms:

• 2-Fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
• 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide
• Benzamide, 2-fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-
• Inc 280
• Incb 28060
• Incb28060
• NC280 BenzaMide,2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-
• Nvp-Inc 280Nx
• Tabrecta
• Capmatinib

2-Fluoro-N-methyl-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

CAS: 1029712-80-8

• Formula: C₂₃H₁₇FN₆O
• Purity: 99%
• Color and Shape: Solid
• Molecular weight: 412.4191

Capmatinib

CAS: 1029712-80-8

• Purity: 99.76%
• Molecular weight: 412.42g/mol

Capmatinib

CAS: 1029712-80-8

Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.

• Formula: C₂₃H₁₇FN₆O
• Purity: 99.24%
• Color and Shape: Solid
• Molecular weight: 412.42

Capmatinib

CAS: 1029712-80-8

Selective c-Met kinase inhibitor

• Formula: C₂₃H₁₇FN₆O
• Purity: Min. 95 Area-%
• Color and Shape: Slightly Yellow Powder
• Molecular weight: 412.42 g/mol